drugset / Trial / NCT06505369
Bispecific T-cell Redirectors as Part of First Line Treatment in Transplant Eligible Multiple Myeloma Patients
NaSequentialOpen-labelTreatment
Summary
This is Phase 2, open-label, multicentre, non-randomised study evaluating participants with newly diagnosed MM eligible for high-dose therapy. The goal of the study is to determine if consolidation with T-cell redirectors - Talquetamab and Teclistamab in sequence will improve the response depth: increase MRD negative CR rate.
Timeline
- Start
- 2024-06-19
- Primary completion
- 2026-11
- Completion
- 2028-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bortezomib | Small molecule | — | Subcutaneous |
| Subject | Daratumumab | Monoclonal antibody | — | Subcutaneous |
| Subject | Dexamethasone | Small molecule | — | Oral |
| Subject | Lenalidomide | Other / unclassified | — | Oral |
| Subject | Talquetamab | Monoclonal antibody | — | Subcutaneous |
| Subject | Teclistamab | Monoclonal antibody | — | Subcutaneous |